June 6th 2023
Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
Roche Canada completes negotiations with the pCPA for VABYSMO® to treat wet AMD and DME
May 30th 2023VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.
Researchers find experimental drug may prevent or slow vision loss in people with diabetes
Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy (GA)
May 26th 2023Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.